Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385399631> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4385399631 abstract "Chronic lymphocytic leukemia (CLL) has long been known for its complications related to immune deregulation, of which autoimmune cytopenias (AIC) were frequently reported. Ibrutinib has dramatically changed the overall prognosis of patients with CLL. However, whether ibrutinib can induce or aggravate AIC in CLL patients is still disputable. Here we report a CLL patient with pure red cell aplasia (PRCA) occurring during ibrutinib treatment and review available data to discuss the possible role of ibrutinib in developing AIC.A 70-year-old female was diagnosed with CLL with indications to initiate ibrutinib treatment given progressive bulky disease. She was admitted for advanced fatigue on the 14th day of ibrutinib monotherapy. A complete blood count revealed severe anemia of hemoglobin (Hb) 37 g/L and a meager reticulocyte count. After excluding other conditions that could cause anemia, PRCA was diagnosed as a complication of CLL.Ibrutinib was discontinued on the day of admission. At the same time, the patient received prednisone and intravenous immunoglobulin (IVIg). Five days later, the Hb did not improve. Cyclosporine A (CsA) was added; IVIg was discontinued, and prednisone was tapered. Ten days later, the Hb had risen to 92 g/L with a high reticulocyte count of 0.279 × 1012/L. The CLL treatment restarted with Zanbrutinib in combination with a low dose of prednisone and CsA. Her CLL was in partial remission by the latest follow-up with an average Hb count.Our case demonstrates a need to evaluate the risk of developing AIC before initiating ibrutinib. For patients with high-risk factors for AIC episodes, the transient addition of other immunosuppressive therapies should be taken into consideration." @default.
- W4385399631 created "2023-07-31" @default.
- W4385399631 creator A5000867726 @default.
- W4385399631 creator A5041096560 @default.
- W4385399631 creator A5055508781 @default.
- W4385399631 creator A5058340142 @default.
- W4385399631 creator A5088942638 @default.
- W4385399631 creator A5089000439 @default.
- W4385399631 date "2023-07-30" @default.
- W4385399631 modified "2023-09-23" @default.
- W4385399631 title "Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia" @default.
- W4385399631 cites W1527533153 @default.
- W4385399631 cites W1659305833 @default.
- W4385399631 cites W1874872148 @default.
- W4385399631 cites W2015510896 @default.
- W4385399631 cites W2057596169 @default.
- W4385399631 cites W2059172186 @default.
- W4385399631 cites W2060359865 @default.
- W4385399631 cites W2098576476 @default.
- W4385399631 cites W2132888287 @default.
- W4385399631 cites W2307952155 @default.
- W4385399631 cites W2549097307 @default.
- W4385399631 cites W2583342918 @default.
- W4385399631 cites W2790385276 @default.
- W4385399631 cites W2883688827 @default.
- W4385399631 cites W2885594994 @default.
- W4385399631 cites W2998606818 @default.
- W4385399631 cites W3135733693 @default.
- W4385399631 cites W3184389017 @default.
- W4385399631 cites W3194553325 @default.
- W4385399631 cites W4298617684 @default.
- W4385399631 cites W4328049399 @default.
- W4385399631 doi "https://doi.org/10.1177/10781552231189192" @default.
- W4385399631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37518980" @default.
- W4385399631 hasPublicationYear "2023" @default.
- W4385399631 type Work @default.
- W4385399631 citedByCount "0" @default.
- W4385399631 crossrefType "journal-article" @default.
- W4385399631 hasAuthorship W4385399631A5000867726 @default.
- W4385399631 hasAuthorship W4385399631A5041096560 @default.
- W4385399631 hasAuthorship W4385399631A5055508781 @default.
- W4385399631 hasAuthorship W4385399631A5058340142 @default.
- W4385399631 hasAuthorship W4385399631A5088942638 @default.
- W4385399631 hasAuthorship W4385399631A5089000439 @default.
- W4385399631 hasConcept C126322002 @default.
- W4385399631 hasConcept C2777422296 @default.
- W4385399631 hasConcept C2777938653 @default.
- W4385399631 hasConcept C2778248108 @default.
- W4385399631 hasConcept C2778461978 @default.
- W4385399631 hasConcept C2778720950 @default.
- W4385399631 hasConcept C2779878957 @default.
- W4385399631 hasConcept C71924100 @default.
- W4385399631 hasConcept C90924648 @default.
- W4385399631 hasConceptScore W4385399631C126322002 @default.
- W4385399631 hasConceptScore W4385399631C2777422296 @default.
- W4385399631 hasConceptScore W4385399631C2777938653 @default.
- W4385399631 hasConceptScore W4385399631C2778248108 @default.
- W4385399631 hasConceptScore W4385399631C2778461978 @default.
- W4385399631 hasConceptScore W4385399631C2778720950 @default.
- W4385399631 hasConceptScore W4385399631C2779878957 @default.
- W4385399631 hasConceptScore W4385399631C71924100 @default.
- W4385399631 hasConceptScore W4385399631C90924648 @default.
- W4385399631 hasFunder F4320324174 @default.
- W4385399631 hasLocation W43853996311 @default.
- W4385399631 hasLocation W43853996312 @default.
- W4385399631 hasOpenAccess W4385399631 @default.
- W4385399631 hasPrimaryLocation W43853996311 @default.
- W4385399631 hasRelatedWork W1511775759 @default.
- W4385399631 hasRelatedWork W2264345925 @default.
- W4385399631 hasRelatedWork W2535639150 @default.
- W4385399631 hasRelatedWork W2954823970 @default.
- W4385399631 hasRelatedWork W3043694179 @default.
- W4385399631 hasRelatedWork W3161155926 @default.
- W4385399631 hasRelatedWork W3172388972 @default.
- W4385399631 hasRelatedWork W3194553325 @default.
- W4385399631 hasRelatedWork W4238721786 @default.
- W4385399631 hasRelatedWork W4385399631 @default.
- W4385399631 isParatext "false" @default.
- W4385399631 isRetracted "false" @default.
- W4385399631 workType "article" @default.